

**REMARKS**


In the instant application, claims 1-48 are pending and have been made the subject of a Restriction Requirement.

The Examiner asserts that Restriction to one of the following inventions is required under 35 U.S.C. § 121:

- I. Claims 1-44 are generic to the following disclosed patentably distinct species: substituted quinazolines, substituted pyridines, substituted piperazines, isoquinolines.
- II. Claims 45-48 are drawn to a process for using compounds and composition of formula (I). Restriction Requirement, page 2.

To comply with the Examiner's Restriction Requirement, Applicants elect Group I, Claims 1-44.

To comply with the Examiner's Election of Species Requirement, Applicants elect the species of the compound of Example 1116, 4-(5-chloro-1H-indole-2-sulfonyl)-6-methoxymethyl-1-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-piperazin-2-one, having the following chemical formula,



a compound wherein:

A is N,

n is 1,

m is 1,

R<sub>1</sub> is H,

R<sub>1a</sub> is H,

R<sub>4</sub> is H,

R<sub>4a</sub> is H,

R<sub>2</sub> is -CH<sub>2</sub>-O-CH<sub>3</sub>,

R<sub>2a</sub> is H,

R<sub>3</sub> and R<sub>3a</sub> taken together form O,

G<sub>1</sub> is L<sub>1</sub>-Cy<sub>1</sub>,

L<sub>1</sub> is SO<sub>2</sub>,

Cy<sub>1</sub> is 5-chloro-1H-indolyl,  
G<sub>2</sub> is L<sub>2</sub>-Cy<sub>2</sub>,  
L<sub>2</sub> is CH<sub>2</sub>, and  
Cy<sub>1</sub> is 1H-pyrrolo[3,2-c]pyridin-2-yl.

Applicants submit that claims 1-4, 7-9, 12, 15, 19-28, 30, 32, 35 and 44 read on the elected species.

Applicants submit that once the compounds of the present invention are found to be novel, then the other Groups defined by the Examiner where appropriate should be subject to rejoinder, pursuant to linking claim practice.

Applicants also affirm their right to file one or more divisional applications with respect to any other non-elected subject matter.

Respectfully submitted,

Date: April 14, 2008

/Jiang Lin/  
Jiang Lin, Reg. No. 51,065  
Attorney for Applicants

Sanofi-aventis U.S. Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-**3582**  
Telefax (908) 231-2626

Sanofi-aventis Docket No. A2575 US CNT1